ScinoPharm Taiwan, Ltd. (TPE: 1789)

Market Cap	17.59B
Revenue (ttm)	3.49B
Net Income (ttm)	399.39M
Shares Out	790.74M
EPS (ttm)	0.51
PE Ratio	44.05
Forward PE	59.33
Dividend	0.30 (1.34%)
Ex-Dividend Date	Jul 4, 2024

Volume	276,681
Average Volume	417,559
Open	22.25
Previous Close	22.35
Day's Range	22.05 - 22.35
52-Week Range	21.40 - 30.50
Beta	0.39
RSI	49.00
Earnings Date	Feb 27, 2025

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2023, ScinoPharm Taiwan's revenue was 3.19 billion, a decrease of -2.39% compared to the previous year's 3.26 billion. Earnings were 287.06 million, a decrease of -18.73%.